Japan Patent Office Invalidates The Word Mark “Bord’or” In Relation To Bordeaux Wines 12/01/2018 by Guest contributor for Intellectual Property Watch 1 Comment In a decision in an invalidation trial jointly claimed by INSTITUT NATIONAL DE L’ORIGINE ET DE LA QUALITE and CONSEIL INTERPROFESSIONNEL DU VIN DE BORDEAUX, the Invalidation Board of Japan Patent Office (JPO) ordered the invalidation of trademark registration no. 5737079 for a word mark “Bord’or” in script fonts (see below) in violation of Article 4(1)(vii) of the Trademark Law, writes Masaki Mikami.
How International IP Policy Reconfigured National Politics: An Interview With Prof. Ken Shadlen 11/01/2018 by Intellectual Property Watch 3 Comments The recently published book Coalitions and Compliance by Professor Ken Shadlen of the London School of Economics examines how international changes can reconfigure domestic politics. Since the late 1980s, developing countries have been subject to intense pressures regarding intellectual property rights. These pressures have been exceptionally controversial in the area of pharmaceuticals. Historically, fearing the economic and social costs of providing private property rights over knowledge, developing countries did not allow drugs to be patented. Now they must do so, an obligation with significant implications for industrial development and public health. This book analyses different forms of compliance with this new imperative in Latin America, comparing the politics of pharmaceutical patenting in Argentina, Brazil, and Mexico. The book focuses on two periods of patent politics: initial conflicts over how to introduce drug patents, and then subsequent conflicts over how these new patent systems function. Intellectual Property Watch recently conducted a Q&A with Prof. Shadlen, which appears below.
US IP Law – A Look At The Year Ahead 11/01/2018 by Steven Seidenberg for Intellectual Property Watch Leave a Comment In the coming year, one US Supreme Court case promises to dominate developments in America’s IP law. The upcoming decision in Oil States Energy Services v. Greene’s Energy Group could have major ramifications for patents, copyrights, trademarks, and the USPTO. But even as that case steals the limelight, 2018 could bring other significant changes to America’s IP law. Here are some of the key developments to watch for.
WIPO Respect For IP Conference To Be Held This Year In South Africa 10/01/2018 by William New, Intellectual Property Watch Leave a Comment In 2018, the World Intellectual Property Organization and other major international organisations are planning the second international conference on “Respect for IP,” referring to raising awareness of and building strategies for enforcement of intellectual property, this time in South Africa.
Artificial Intelligence Holds Enticing Promise, Needs Framework, Say OECD, Microsoft, IEEE 10/01/2018 by Catherine Saez, Intellectual Property Watch Leave a Comment As artificial intelligence technology spreads its wings, governance issues are emerging, as are international discussions, including a range of activities planned for 2018. One of the panels of the December Internet Governance Forum in Geneva explored the policy questions, as panellists said artificial intelligence is unabatedly spreading to many areas of our lives with promises of economic growth and benefits, but with few regulations to frame it. Issues include ethics, privacy, biases, and lack of transparency.
Year Ahead: US Music Sector Calls For Major Legislative Changes To Copyright In 2018 09/01/2018 by Emmanuel Legrand for Intellectual Property Watch Leave a Comment The music community is ramping up its efforts to have significant new copyright legislation approved by United States Congress in 2018, amid key changes in the legislative apparatus, with the elevation of Rep. Jerold Nadler (D-New York) as the Ranking Member of the House Judiciary Committee, a pivotal role that puts him at the heart of the US legislative system, and the retirement of the Committee’s current Chairman, Bob Goodlatte (R-Virginia), at the end of the year.
WHO: New Directors In Leadership Team Selected On Merit First 09/01/2018 by William New, Intellectual Property Watch Leave a Comment The new World Health Organization director general last month announced a range of officials to serve as programme directors, touting the unusual achievement of naming almost all women to add to an overall women’s majority in the senior leadership of the organisation – a first for the UN. Now after some questions arose over the choice of a Russian official to head up efforts against tuberculosis, the WHO defended its choices as fully merit-based, including in an email to Intellectual Property Watch and its sister publication Global Health Policy News.
WTO Stalemate Concerns Include Non-Violation Complaints, E-Commerce; TRIPS Health Amendment Extended 08/01/2018 by Monika Ermert for Intellectual Property Watch Leave a Comment A few weeks after the failure of the World Trade Organization ministerial meeting in Buenos Aires to cut deals advancing issues from fisheries to e-commerce, some governments and trade experts around the world are concerned about the WTO’s future. Meanwhile, a couple of intellectual property-related provisions moved ahead after the ministerial without change.
Medicines Patent Pool Launches Search For Next Director 08/01/2018 by William New, Intellectual Property Watch Leave a Comment A negotiator and fundraiser with extensive experience with the pharmaceutical industry. Those are some of the qualities the next Medicines Patent Pool executive director might have, according to a just-posted job announcement.
WHO’s Revised Work Programme: Evidence-Based Normative Work, Access To Medicines 08/01/2018 by Catherine Saez, Intellectual Property Watch Leave a Comment In a couple of weeks, the World Health Organization will be holding its annual January Executive Board meeting. Delegates will consider the edited version of the draft 13th WHO general programme of work for 2019-2023, published on 5 January. Following comments to the first version of the programme in November, the secretariat produced a more fleshed-out document, emphasizing the WHO’s normative role, in particular evidence-based. The necessity of access to medicines and vaccines has been extended to other products, such as devices and blood products, and mention is made of the WHO Global Strategy and Plan of Action on Public Health, Innovation and Intellectual Property.